Miconazole is an imidazole antifungal agent, developed by Janssen Pharmaceutica, commonly applied topically to the skin or to mucous membranes to cure fungal infections. It works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. It can also be used against certain species of Leishmania protozoa which are a type of unicellular parasites that also contain ergosterol in their cell membranes. In addition to its antifungal and antiparasitic actions, it also has some antibacterial properties. It is marketed in various formulations under various brand names.
Starting at
(RS)-1-(2-(2,4-Dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole |
Trade names | Desenex, Monistat, Zeasorb-AF |
AHFS/Drugs.com | monograph |
MedlinePlus | a601203 |
Pregnancy category |
AU: A US: C (Risk not ruled out) In Australia, it is category A when used topically. In the US, the pregnancy category is C for oral and topical treatment. |
Legal status |
AU: S2 (Pharmacy only) UK: POM (Prescription only) US: OTC Schedule 2 in Australia for topical formulations, schedule 3 (Aus) for vaginal use and for oral candidiasis, otherwise schedule 4 in Australia |
Routes of administration |
topical, vaginal, sublabial, oral |
Bioavailability | n/a |
Metabolism | n/a |
Biological half-life | n/a |
Excretion | n/a |
CAS Number | 22916-47-8 |
ATC code | A01AB09 A07AC01 D01AC02 G01AF04 J02AB01 S02AA13 |
PubChem | CID: 4189 |
IUPHAR/BPS | 2449 |
DrugBank | DB01110 |
ChemSpider | 4044 |
UNII | 7NNO0D7S5M |
KEGG | D00416 |
ChEBI | CHEBI:6923 |
ChEMBL | CHEMBL91 |
Formula | C18H14Cl4N2O |
Molecular mass | 416.127 g/mol |
SMILES[show] |
|
InChI[show] |